Concepta PLC Change of Broker (7367A)
January 02 2018 - 7:52AM
UK Regulatory
TIDMCPT
RNS Number : 7367A
Concepta PLC
02 January 2018
2 January 2018
Concepta plc
("Concepta" or the "Company")
Change of broker
Concepta plc (AIM: CPT) the UK healthcare company and developer
of a proprietary product targeted at the mobile health market with
a primary focus on women's fertility, today announces that Beaufort
Securities Limited has ceased to act as the Company's joint broker
with immediate effect. NOVUM Securities Limited remains as the
Company's sole broker.
ENDS
Enquiries:
The Company
Erik Henau
CEO
Tel: +44 (0) 1234 866601
SPARK Advisory Partners Limited (Nomad)
Neil Baldwin / Mark Brady
Tel: +44 (0)20 368 3550
NOVUM Securities Limited (Broker)
Colin Rowbury
+44 (0) 20 7399 9400
Yellow Jersey (Financial PR)
Georgia Colkin / Joe Burgess / Katie Bairsto
Tel: +44 (0) 776 932 5254
About Concepta Plc:
Concepta plc is an AIM-quoted pioneering UK healthcare company
that has developed a proprietary product, myLotus, targeted at the
personalised mobile health market with a primary focus on
unexplained infertility* in women.
myLotus is currently the only consumer product which allows both
quantitative and qualitative measurements of a woman's personal LH
and hCG* hormone levels in a home test, facilitating higher
conception rates and early diagnosis of issues with fertility
hormones. The proposition of myLotus is to help women conceive
naturally.
Concepta has made significant progress recently, establishing
agreements with a number of distributors in China where myLotus has
been given cFDA approval. Concepta is initially targeting the
traditional route to market in China through Chinese hospitals and
plans to add the direct-to-consumer route in the near future.
The Company is also well on its way to achieving CE-marking and
commencing its direct-to-consumer launch in the UK and Europe in H1
2018. The Company has identified a significant global market
opportunity, with revenue potential of the Chinese and EU
unexplained infertility market estimated to be worth c.GBP600m per
annum.
*Unexplained infertility refers to women that have been unable
to conceive after 6 months of trying. This highly motivated target
group of consumers won't typically be offered medical intervention
until 12 months of unsuccessfully trying, with IVF not offered
until two years. Research indicates couples start to take positive
action ahead of this time and there is little medical support to
help them do so.
This information is provided by RNS
The company news service from the London Stock Exchange
END
APPUGUBCGUPRGPP
(END) Dow Jones Newswires
January 02, 2018 07:52 ET (12:52 GMT)
Myhealthchecked (LSE:MHC)
Historical Stock Chart
From Mar 2024 to Apr 2024
Myhealthchecked (LSE:MHC)
Historical Stock Chart
From Apr 2023 to Apr 2024